Pharvaris

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Pharvaris clocks a pivotal win in race for rapid HAE relief

Pharvaris hit its primary endpoint, positioning the biotech to file for approval of a challenger to KalVista’s Ekterly in a rare genetic disease.
Nick Paul Taylor Dec 3, 2025 9:10am
Go sign green light

FDA lifts remaining hold on Pharvaris’ HAE drug

Jan 22, 2024 7:32am
finch canary cage free bird release

Pharvaris oral hereditary angioedema med cuts attacks in phase 2

Dec 6, 2023 10:18am
FDA

Pharvaris runs tox test to reverse clinical hold for HAE asset

Jan 9, 2023 10:42am
parachutes

Ex-Pfizer R&D head Abraham joins Vividion—Chutes & Ladders

Feb 14, 2020 9:30am
Exit sign

Pharvaris nabs Shire exec as new CMO

Feb 7, 2020 9:22am